^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MFI2 expression

i
Other names: MFI2, MELTF, Melanotransferrin, Antigen P97 (Melanoma Associated) Identified By Monoclonal Antibodies 133.2 And 96.5, Membrane-Bound Transferrin-Like Protein, Melanoma-Associated Antigen P97, MAP97, MFI2, CD228 Antigen, CD228, MTF1
Entrez ID:
4ms
The E2F1/MELTF axis fosters the progression of lung adenocarcinoma by regulating the Notch signaling pathway. (PubMed, Mutat Res)
Together, our outcomes demonstrated that E2F1 fostered LUAD progression by activating MELTF via the Notch signaling activity. Hence, MELTF emerged as a feasible target for treating LUAD.
Journal
|
NOTCH1 (Notch 1) • MELTF (Melanotransferrin) • HES1 • E2F1 (E2F transcription factor 1)
|
NOTCH1 expression • MELTF expression • MFI2 expression
|
RG4733
8ms
Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia. (PubMed, Biochem Genet)
In addition, APTO-253 has the potential to become an AML-targeted drug. The cuproptosis-related genes MTF1 and LIPT1 can be used as prognostic biomarkers in AML. A total of six lncRNAs, including MALAT1, are involved in the expression and regulation of MTF1 in AML through six miRNAs such as hsa-miR-32-5p.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NPM1 (Nucleophosmin 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • DLAT (Dihydrolipoamide S-Acetyltransferase) • MELTF (Melanotransferrin) • FDX1 (Ferredoxin 1) • LIAS (Lipoic Acid Synthetase) • LIPT1 (Lipoyltransferase 1) • MTF1 (Metal Regulatory Transcription Factor 1) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1) • SLC31A1 (Solute Carrier Family 31 Member 1)
|
NPM1 mutation • MFI2 expression
|
APTO-253
9ms
The biological significance of cuproptosis-key gene MTF1 in pan-cancer and its inhibitory effects on ROS-mediated cell death of liver hepatocellular carcinoma. (PubMed, Discov Oncol)
In addition, in vitro experiment indicated knockdown of MTF1 resulted in the suppressed cell proliferation, increased reactive oxygen species (ROS) and promoted cell death in LIHC cells HepG2 and Huh7. Taken together, this pan-cancer analysis of MTF1 has implicated that MTF1 could play an essential role in the progression of various human cancers.
Journal • Pan tumor
|
CD8 (cluster of differentiation 8) • MELTF (Melanotransferrin) • MTF1 (Metal Regulatory Transcription Factor 1)
|
MFI2 expression
11ms
MTF1 has the potential as a diagnostic and prognostic marker for gastric cancer and is associated with good prognosis. (PubMed, Clin Transl Oncol)
MTF1 is relatively lowly expressed in gastric cancer. MTF1 is also an independent prognostic factor for gastric cancer patients and is associated with good prognosis. It has the potential to be a diagnostic and prognostic marker for gastric cancer.
Journal • IO biomarker
|
MELTF (Melanotransferrin)
|
MFI2 expression
12ms
SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models. (PubMed, Mol Cancer Ther)
Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity. SGN-CD228A is being investigated in an ongoing Phase I clinical trial (NCT04042480) in patients with advanced solid tumors.
Preclinical • Journal
|
MELTF (Melanotransferrin)
|
MELTF expression • MFI2 expression
|
SGN-CD228A
1year
Exosomal MFI2-AS1 sponge miR-107 promotes non-small cell lung cancer progression through NFAT5. (PubMed, Cancer Cell Int)
We demonstrate that MFI2-AS1 is upregulated in exosomes secreted by metastatic NSCLC cells and can be transferred to HUVECs, promoting angiogenesis and migration.
Journal
|
MELTF (Melanotransferrin)
|
MFI2 expression
1year
SGN-BB228, a CD228-directed costimulatory antibody anticalin® bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T cell exhaustion (AACR 2023)
Interestingly, in this system, anti-PD-1 (nivolumab) failed to reinvigorate functionally exhausted T cells despite high PD-L1 expression by tumor cells. Together these data highlight SGN-BB228, a first-in-class, investigational CD228 x 4-1BB costimulatory Antibody Anticalin® bispecific with potent and CD228-conditional 4-1BB costimulatory activity with therapeutic potential in multiple solid tumor types. These data support the first-in-human phase 1 clinical trial of SGN-BB228 in advanced melanoma and other solid tumors (NCT05571839), which is currently recruiting.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • MELTF (Melanotransferrin)
|
PD-L1 expression • PD-L1 overexpression • MELTF expression • MFI2 expression
|
Opdivo (nivolumab) • PF-08046049
over1year
SGN-BB228 is a first-in-class CD228-targeted costimulatory Antibody Anticalin bispecific delivering potent and conditional 4-1BB costimulation to tumor-specific T cells (SITC 2022)
Conclusions Together these data introduce SGN-BB228, a first-in-class, investigational CD228/4-1BB costimulatory Antibody Anticalin® bispecific with potent and CD228-conditional 4-1BB costimulatory activity with therapeutic potential in multiple solid tumor types. These data support future clinical study of SGN-BB228 in a first-in-human Phase 1 trial.
IO biomarker
|
TNFRSF9 (TNF Receptor Superfamily Member 9) • MELTF (Melanotransferrin)
|
MFI2 expression
|
PF-08046049
over1year
Reduced N6-methyladenosine mediated by METTL3 acetylation promotes MTF1 expression and hepatocellular carcinoma cell growth. (PubMed, Chem Biodivers)
Importantly, overexpression of MTF1 prompted HCC cell proliferation and was associated with poor prognosis. In conclusion, the METTL3-METTL14-WTAP complex was regulated by acetylation induced by sulfatide to control MTF1 m6A methylation and its mRNA transcription, which was important for the tumor growth and migration of HCC.
Journal
|
HDAC2 (Histone deacetylase 2) • MELTF (Melanotransferrin) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein)
|
MFI2 expression
over1year
Identification of key genes of the ccRCC subtype with poor prognosis. (PubMed, Sci Rep)
It was shown that MFI2, CP, FGA, and FGG expression can predict the response to sunitinib, while the APOB, ENAM, IGFBP1, and MFI2 expression predict the response to nivolumab. The results obtained provide insight into the genetic characteristics underlying the aggressive subtype of ccRCC and may help develop new approaches to the treatment of this disease.
Journal • PD(L)-1 Biomarker
|
IL6 (Interleukin 6) • APOB (Apolipoprotein B) • MELTF (Melanotransferrin)
|
MFI2 expression
|
Opdivo (nivolumab) • Sutent (sunitinib)
almost2years
Long non-coding MELTF Antisense RNA 1 promotes and prognosis the progression of non-small cell lung cancer by targeting miR-1299. (PubMed, Bioengineered)
In addition, through luciferase activity analysis and bioinformatics analysis, MELTF-AS1 has a negative effect on miR-1299, and silencing MELTF-AS1 enhanced miR-1299 expression in NSCLC cells. MELTF-AS1 is highly likely to be a promising prognostic biomarker, and associated with the progression of NSCLC.
Journal
|
MELTF (Melanotransferrin)
|
MFI2 expression
2years
MFI2-PREDICT: Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers (clinicaltrials.gov)
P=N/A, N=260, Recruiting, University Hospital, Strasbourg, France | Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Dec 2024 | Initiation date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2022 --> Dec 2021
Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
MELTF (Melanotransferrin)
|
MFI2 expression
over2years
lncRNA MELTF-AS1 facilitates osteosarcoma metastasis by modulating MMP14 expression. (PubMed, Mol Ther Nucleic Acids)
Furthermore, the results of RNA pull-down assays, luciferase reporter assays, and RNA immunoprecipitation (RIP) assays revealed that MELTF-AS1 could regulate MMP14 expression through interaction with miR-485-5p. Our study suggested that MELTF-AS1 functioned as a pro-metastasis gene in osteosarcoma by upregulating MMP14 and that it could be a potential therapeutic and diagnostic target for osteosarcoma.
Journal
|
MELTF (Melanotransferrin)
|
MFI2 expression
over2years
Clinical • New trial
|
MELTF (Melanotransferrin)
|
MFI2 expression
over3years
The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer. (PubMed, Cell Death Dis)
We propose that the expressions and functions of the two forms of MFI2 in lung cancer are relatively independent. Specifically, mMFI2 was a potential lung cancer therapeutic target, while sMFI2 was highly enriched in advanced lung cancer, and could be used as a tumor staging index.
Journal
|
MELTF (Melanotransferrin)
|
MFI2 expression
almost4years
Bioinformatics profiling integrating a three immune-related long non-coding RNA signature as a prognostic model for clear cell renal cell carcinoma. (PubMed, Cancer Cell Int)
Additionally, the expression levels of lncR-MELTF-AS1 and IL10RB-DT were remarkably enhanced along the more advanced T-stages, but the lncR-ATP1A1-AS1 showed the inverse gradient. Our results demonstrate some sIRlncRs with remark clinical relevance show the latent monitoring and prognosis values for ccRCC patients and may provide new insight in immunological researches and treatment strategies of ccRCC patients.
Journal
|
MELTF (Melanotransferrin)
|
MFI2 expression